School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK; Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Warsaw, Poland.
School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK.
Int J Pharm. 2021 Apr 1;598:120305. doi: 10.1016/j.ijpharm.2021.120305. Epub 2021 Feb 1.
In an era moving towards digital health, 3D printing has successfully proven its applicability in providing personalised medicine through a technology-based approach. Among the different 3D printing techniques, direct extrusion 3D printing has been demonstrated as a promising approach for on demand manufacturing of solid dosage forms. However, it usually requires the use of elevated temperatures and/or the incorporation of an evaporable solvent (usually water). This can implicate the addition of a drying step, which may compromise the integrity of moisture- or temperature-sensitive drugs, and open the door for additional quality control challenges. Here, we demonstrate a new approach that simplifies direct extrusion 3D printing process with the elimination of the post-printing drying step, by merely adding a fatty glyceride, glyceryl monostearate (GMS), to a model drug (theophylline) and permeable water insoluble methacrylate polymers (Eudragit RL and RS). Indeed, rheological studies indicated that the addition of a combination of a plasticiser, (triethyl citrate), and GMS to theophylline: methacrylate polymer blends significantly reduced the extensional viscosity (to <2.5 kPa·Sec) at 90 °C. Interestingly, GMS demonstrated a dual temperature-dependant behaviour by acting both as a plasticiser and a lubricant at printing temperature (90-110 °C), while aiding solidification at room temperature. X-ray powder diffraction indicated incomplete miscibility of GMS within the polymeric matrix at room temperature with the presence of a subtle diffraction peak, at 2(Θ) = 20°. The 3D printed tablets showed acceptable compendial weight and content uniformity as well as sufficient mechanical resistance. In vitro theophylline release from 3D printed tablets was dependant on Eudragit RL:RS ratio. All in all, this work contributes to the efforts of developing a simplified, facile and low-cost 3D printing for small batch manufacturing of bespoke tablets that circumvents the use of high temperature and post-manufacturing drying step.
在迈向数字医疗的时代,3D 打印技术已成功证明其可通过基于技术的方法提供个性化药物。在不同的 3D 打印技术中,直接挤压 3D 打印已被证明是按需制造固体剂型的有前途的方法。然而,它通常需要使用升高的温度和/或掺入可蒸发溶剂(通常为水)。这可能意味着需要增加干燥步骤,这可能会损害对湿度或温度敏感的药物的完整性,并为额外的质量控制挑战打开大门。在这里,我们展示了一种新方法,通过在模型药物(茶碱)和可渗透的水不溶性甲基丙烯酸酯聚合物(Eudragit RL 和 RS)中添加脂肪甘油酯(单硬脂酸甘油酯)(GMS),可以简化直接挤压 3D 打印过程,而无需进行后印刷干燥步骤。实际上,流变学研究表明,在茶碱:甲基丙烯酸酯聚合物混合物中添加增塑剂(柠檬酸三乙酯)和 GMS 的组合可显著降低 90°C 时的拉伸粘度(至<2.5kPa·Sec)。有趣的是,GMS 在打印温度(90-110°C)下表现出双重温度依赖性行为,既作为增塑剂又作为润滑剂,同时有助于在室温下固化。X 射线粉末衍射表明,GMS 在室温下与聚合物基质不完全混溶,存在微妙的衍射峰,在 2(Θ)= 20°处。3D 打印片剂具有可接受的药典重量和含量均匀性以及足够的机械强度。茶碱从 3D 打印片剂中的体外释放取决于 Eudragit RL:RS 比。总而言之,这项工作有助于开发简化,简便且低成本的 3D 打印技术,用于定制片剂的小批量制造,从而避免使用高温和后制造干燥步骤。